Navigation Links
LegalView Reveals Details of the FDA Mandated Black Box Warning For Fluoroquinolone Antibiotics Such as Cipro and Levaquin
Date:7/12/2008

LegalView reported of a recent FDA warning for antibiotics under the fluoroquinolones drug family that will now require a black box warning, the strongest warning issued by the FDA. The FDA instituted the mandate due to the greater risk of tendonitis and tendon rupture among patients prescribed these drugs.

Denver (PRWEB) July 12, 2008 -- LegalView, the number one resource for everything legal on the Internet, reported details of a recent U.S. Food and Drug Administration (FDA) mandate regarding the fluoroquinolones antibiotics family of drugs. All of the fluoroquinolones will now carry black box warning labels to ensure physicians and patients understand that the drugs have been associated with an increased risk of tendonitis and tendon rupture.

Among the most common of the fluoroquinolone antibiotics are Levaquin, Cipro, Factive and Avelox - some of the most commonly prescribed anti-bacterial drugs. Levaquin, also known as levofloxacin, is an antibiotic that fights infections including bronchitis, pneumonia, Chlamydia, gonorrhea, skin infections, urinary tract infections, etc. It has been previously linked to Achilles tendonitis among patients who were prescribed the drug. A study released in The Journal of American Board of Family Medicine reported the Levaquin warning and associated risks with prescribing the drug, however, the drug was approved for the use of children as an antibiotic and potential treatment for airborne anthrax in 2008 only a few years after the report was published. According to the study, patients who had taken the drug at any time, even two years or prior, may be at an increased risk for tendonitis. And those who were elderly seemed to be at the highest risk. Individuals who have taken Levaquin are advised to contact an experienced pharmaceutical attorney to learn about the potential for developing a Levaquin lawsuit.

Cipro, known as ciprofloaxacin, is manufactured and sold by Bayer A.G. and is used to treat bacterial infections, although it is not recommended for victims of the common cold or flu. A study published in the Clinical Rheumatology December 2003 issue, noted the relationship of the drug's consumption compared to patients with Achilles' tendon rupture and reported that there may be cause for a Cipro warning that links the drug's use to the risk of tendonitis. In addition to this risk, other Cipro side effects can include seizure, difficulty breathing, hallucinations, depression, blacking out, chest pain, suicidal thoughts and numbness.

Another one of the more commonly used drugs that is part of the fluoroquinolones group is Factive. Factive, gemifloxacin mesylate, is an oral prescription drug that has also been linked to the tendon rupture as the most serious risk, although some other Factive side effects can be considered just as serious, including phototoxicity, abnormal heartbeats and central nervous system conditions. The drug was released for market in April 2003 from Oscient Pharmaceuticals with the tendonitis Factive warning printed on an informational pamphlet issued by the company, although it was not at that time marketed with a black box warning even though the risks of Achilles' tendon rupture were known among the manufacturers. Factive, similar to Cipro and Levaquin, treats lung bacterial infections for patients 18 years and older.

Finally, adult patients who have been taking Avelox (moxifloxacin HCL) for treatment of either bacterial sinusitis, bronchitis or pneumonia infections should be aware that an Avelox warning and increase of a black box labeling will also be issued per the FDA's mandate. Because Avelox is part of the fluoroquinolones antibiotic group, the Avelox side effects also consists of an increased risk for tendonitis or tendon tear/rupture.

It is important for individuals who have taken or are currently taking any of these drugs (Levaquin, Cipro, Factive and Avelox) or any of the other fluoroquinolones antibiotics be aware of this increased warning and FDA mandate, as the potential for a prescription drug lawsuit may exist, especially if a patient that previously consumed any of these drugs has suffered from Achilles tendon rupture. It is advisable for a victim to contact an experienced pharmaceutical law firm to receive legal consultation for possible fluoroquinolone-related litigation. It is also important for patients to contact their physician immediately if muscle soreness or tenderness occurs while consuming any of these anti-bacterial prescription drugs, as this may be a sign of tendon rupture.

About LegalView:

LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView.

###


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. Brain imaging reveals breakdown of normal emotional processing
2. Survey reveals disparities in skin cancer knowledge, protection among high school students
3. Large intensive care study reveals vital recommendations for treatment of brain injury patients
4. Inc. Magazine Reveals Its 26th Annual List of Americas 500 Fastest-Growing Private Companies
5. Survey From The Partnership and MetLife Foundation Reveals Important Role Todays Grandparents Play in Teens Lives
6. New Survey Reveals Kidney Patients Concern About Medicare Policies
7. UCSD study reveals the regulatory mechanism of key enzyme
8. UCSD study reveals the regulatory mechanism of key enzyme
9. Poll reveals public awareness of nanotech stuck at low level
10. Survey reveals ignorance and confusion about cancer amongst the elderly
11. Story Reveals How Isabel and Her Family Learn About Bone Health and Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , ... February 08, 2016 , ... Delta Dental of ... help combat pancreatic cancer. , Gary D. Radine, who recently retired as president and ... American Cancer Society’s 2015 CEO of the Year , helped lead the effort ...
(Date:2/8/2016)... ... February 08, 2016 , ... Discover the Rocky Mountain region’s longest ... and 700 companies. Attendees also get to see the most incredible gardens and ... Home Show , at the Colorado Convention Center - 700 14th St. Denver CO, ...
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi is offering ... 2016 in honor of his birthday on February 10th. During this time, people ... is known by over 250,000 people from over 40 different countries as an “ordinary ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... empowers employers and organizations with the tools and information to lower the costs, ... to cut the cost of providing employee healthcare benefits by as much as ...
(Date:2/6/2016)... ... ... Shark Finds and Kevin Harrington, along with the Product Managers ... Belly Bands. , Having a dog is great—except when it wets every couch, bed, ... works, get Belly Bands, the easiest way to stop dogs from wetting on ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... year-end 2015 results after the Nasdaq market closes on ... live conference call and webcast to discuss its financial ... 11, 2016 at 4:30 p.m. Eastern Time (1:30 p.m. ... http://www.neurocrine.com . --> Participants can access the ...
(Date:2/8/2016)... 8, 2016 --> ... report "Ablation Technologies Market by Product (Radiofrequency, Ultrasound, Irreversible ... Cosmetic Surgery, Ophthalmology, Gynecology) - Global Forecasts to 2020", ... over the forecast period of 2015 to 2020. The ... at CAGR of 10.5% from 2015 to 2020. ...
(Date:2/8/2016)... 8, 2016 Nueterra, the nation,s ... in the development of equity partnerships and ... has divided its interests between two new ... will continue the founding company,s private equity ... a national system of integrated provider networks ...
Breaking Medicine Technology: